Interviews with Pharma and Biotech Global Leaders
Refine Search
Pharmaceutical
The promise being shown by plinabulin, not just as a natural compound that could provide multiple potential therapeutic benefits in a variety of cancers but also as an agent that mitigates the side effects and improves the efficacy of an established chemotherapy treatment, is enormous. 16 November 2016
Pharmaceutical
Immuno-oncology company PsiOxus Therapeutics may opt for an initial share offering in 2017, though the company is not looking to go public anytime sooner, chief executive John Beadle told The Pharma Letter in an exclusive interview. 4 November 2016
Biotechnology
The young Chinese venture-capital backed biotech company Ambrx has received some good news recently. 31 October 2016
Pharmaceutical
Cham Herath, medical director at Italian drugmaker Chiesi Farmaceutici, knew that news of his company’s progress this month with a first-of-its-kind triple combination in chronic obstructive pulmonary disease (COPD) might not gain as much attention as it probably should, for two reasons. 3 October 2016
Pharmaceutical
Thierry Diagnana, head of the Novartis Institutue for Tropical Diseases (NITD), speaks to the Pharma Letter’s Katie Osborne about a new anti-malarial molecule, KAF156, which could be a game-changer in the treatment landscape. 23 September 2016
Generics
As a major member of Fosun Pharma family, Chongqing-based Yao Pharma is a key part of Fosun Pharma’s global strategy. 22 September 2016
Biosimilars
Much like its parent company Fosun Group, China’s Fosun Pharma also likes to shop. 21 September 2016
Biotechnology
British-born Christian Hogg can say with some confidence that the milestone of a Chinese company taking a drug candidate from discovery all the way to global registration will be achieved within the next two to three years. 19 September 2016
Biotechnology
The discussion about anti-infective products and drug-resistant pathogens has become one of the biggest issues in health care internationally. 12 September 2016
Biotechnology
Ajan Reginald does not dispute the ability of life-saving cellular therapies to reach patients – and backs regulators’ moves to make this happen quicker through conditional approvals. 30 August 2016
Pharmaceutical
The use of esketamine as a treatment for major depressive disorder (MDD) could transform the treatment landscape and prevent thousands of people from taking their own lives, according to scientists at Janssen Pharmaceuticals. 20 August 2016
Biotechnology
At a time when the inability of UK patients to access certain potentially lifesaving cancer drugs has come under fire, one company executive has praised the stance taken by the British government on a treatment of advanced renal cell carcinoma (RCC). 17 August 2016
Biosimilars
The companies aiming to take advantage of patent expiries of some of the world’s best-selling biologics – be they the Sandoz unit of Swiss pharma giant Novartis, US biotech majors Amgen and Biogen or others of similar ilk – are some of the industry’s big players. 5 August 2016
Biotechnology
From its academic origins to its innovative assets, bold business strategy and the targeting of an unmet need, Chronos Therapeutics is the sort of company which embodies the biotech revolution. 28 July 2016
Biotechnology
Treating the symptoms of Alzheimer’s is akin to painting the lines on a bridge that is collapsing, says Elliot Goldstein, chief executive of ProMIS Neurosciences, as his company prepares to present some of its research at the Alzheimer’s Association International Conference (AAIC). 27 July 2016
Pharmaceutical
Having spent 24 years working closely with pharma companies and regulators for one of the industry’s leading contract research organizations (CROs), Alberto Grignolo is highly qualified to talk about trends in the sector and the impact of changes on drug development. 25 July 2016
Biosimilars
The race to come up with a biosimilar version of the rheumatoid arthritis treatment Humira (adalimumab) – the world’s top-selling drug – is well and truly on. 18 July 2016
Pharmaceutical
The head of Eisai in Europe has pledged to subsidize the cost of thyroid cancer drug Lenvima (lenvatinib) if health bosses agree to include it in the revamped Cancer Drugs Fund (CDF). 14 July 2016
Pharmaceutical
Novartis might have a long heritage in leading antimalarial drug development, but there is a new awareness that it needs to bring forward therapies that treat the disease in a different way, says David Hughes, senior global program head in clinical development at the Swiss pharma giant. 5 July 2016
Biosimilars
It is no secret that companies which are able to successfully develop biosimilar versions of big-selling biologics in the next five to 10 years will be onto a good thing. 1 July 2016
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Pharmaceutical
Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care. 21 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
Pharmaceutical
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
Pharmaceutical
Plenty of companies in the pharmaceutical industry talk the talk when it comes to focusing on patients. 6 August 2024
Biotechnology
It is not every day that an Italian biotech company raises 23 million euros ($24.7 million) in a Series A financing. 17 June 2024
Pharmaceutical
Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. 4 June 2024
Interview
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight. 3 June 2024
Biotechnology
Marc de Garidel, chief executive of French clinical-stage biotech Abivax (Nasdaq: ABVX), has good reason for his belief in the company’s pioneering lead asset, obefazimod. 13 May 2024
Pharmaceutical
A Q&A with the man who heads the UK business of the privately-held Italian drugmaker. 3 May 2024
Pharmaceutical
Privately-held Isotope Technologies Munich (ITM) is not just the radiopharmaceutical company that can do it all - from manufacturing and supplying medical radioisotopes to developing a broad precision oncology pipeline, including two Phase III studies. 26 April 2024
Biotechnology
German firm Tubulis has just announced a 128 million euros ($138.8 million) Series B2 financing. 15 March 2024
Pharmaceutical
Staying true to her values is not a secondary consideration for Dr Dennise Broderick in her career and leadership of Galen, but rather is front and central to every action she takes. 7 March 2024
Biotechnology
Since the approval of the first CAR-T in 2017, T cell therapies have revolutionized the treatment of some blood cancers, and are one of the few cancer treatments to drive cures. 12 February 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze